Evidence map›Paper›PMID 42348779›Full record

ArticleArchives of endocrinology and metabolism2026

Clinical characteristics, glycemic control & quality of life of patients using Android Artificial Pancreas System (AAPS) in Brazil.

Gabriella Lopes Ventura, Laryssa da Silva Messias, Maria Eduarda Pereira Dantas, Milena Oliveira Leite, Débora Souto, Maria de Lourdes Passos Machado, Edson Perrotti, Thiago Mota Soares, Tassia Virginia de Carvalho Oliveira, Lenita Zajdenverg and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabriella Lopes VenturaUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Laryssa da Silva MessiasUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Maria Eduarda Pereira DantasUniversidade Tiradentes Aracaju SE Brasil Universidade Tiradentes, Aracaju, SE, Brasil.
Milena Oliveira LeiteUniversidade Tiradentes Aracaju SE Brasil Universidade Tiradentes, Aracaju, SE, Brasil.
Débora SoutoUniversidade Federal do Rio de Janeiro Departamento de Nutrologia e Diabetes Rio de Janeiro RJ Brasil Departamento de Nutrologia e Diabetes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Maria de Lourdes Passos MachadoUniversidade Tiradentes Aracaju SE Brasil Universidade Tiradentes, Aracaju, SE, Brasil.
Edson PerrottiUniversidade Federal de Alagoas Maceió AL Brasil Universidade Federal de Alagoas, Maceió, AL, Brasil.
Thiago Mota SoaresUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Tassia Virginia de Carvalho OliveiraUniversidade Tiradentes Aracaju SE Brasil Universidade Tiradentes, Aracaju, SE, Brasil.
Lenita ZajdenvergUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Joana DantasUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Melanie RodackiUniversidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study evaluated the safety and efficacy of the Android Artificial Pancreas System (AAPS) in Brazilians with type 1 diabetes mellitus (T1D). SUBJECTS AND

methodsA total of 371 participants were surveyed, including 62 AAPS users and 309 non-users. AAPS configurations included continuous glucose monitoring (CGM ), Bluetooth transmitter (MiaoMiao), and a non-automated insulin pump.

resultsAAPS users had a mean Time in Range (TIR) of 78.5% ± 16.6, with HbA1c levels decreasing from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001). Compared to non-AAPS users, AAPS users demonstrated better glycemic control, fewer severe hypoglycemic events (p = 0.006), and improved quality of life (p < 0.0001). However, 23.08% of AAPS users had a TIR below 70%, and time in level-2 hypoglycemia exceeded recommendations.

conclusionThese findings highlight AAPS as a low-cost alternative to commercial systems, with potential to expand access to automated therapy globally, particularly in resource-limited settings.

Indexed as

Diabetes Mellitus, Type 1Glycemic ControlPancreas, ArtificialQuality of LifeAdolescentAdultBlood GlucoseBrazilContinuous Glucose MonitoringFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinInsulin Infusion SystemsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinartificial pancreasautomated insulin delivery systemsglycemic controlquality of lifeType 1 diabetes

Identifiers

PMID42348779
PMCPMC13299508

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.